
Always Better When We're Together: A novel, multi-stakeholder coalition enhances national

guidelines for hereditary cancer testing and detection

Emily K. Dalton, Robert Pilarski, Lauren Sferrazza, Jessica Grzybowski, Ann Marie Miller, Shelly Cummings, Kelli Conlan, Kristen Postula, Rebecca Johnson, Lisa Schlager, Robin Dubin, Fred Struve

BACKGROUND

Clinical guidelines must evolve along with ongoing research findings. To assist this, the Inter-Organization Cancer Genetics Clinical Evidence Coalition (INTERACT) was established in 2020 among leading laboratory, industry, and patient groups.



Inter-Organization Cancer Genetics Clinical Coalition

METHODS

- Assess opportunities to expand appropriate testing criteria within guidelines.
- Letters are reviewed and approved by each member organization and submitted through the NCCN submission request process.

CONCLUSIONS

- A diverse group of stakeholders from industry and patient advocacy can successfully work together to increase access to appropriate hereditary cancer testing
- •INTERACT has impacted NCCN testing guidelines for hereditary cancer testing through their submission and transparency process
- There is utility and value in coordinated collaboration

Figure 1: Timeline of INTERACT Activities

INTERACT established

- First letter submitted: CRC* guideline, v1.2020
- Successful request to change threshold for PREMM5 risk model

5 NCCN requests approved

- BOP**
- CRC*
- Uterine Neoplasms 23 total requests made

4 NCCN requests approved

- CRC*
- Kidney Cancer
- 20 total requests made

2 NCCN requests approved

- CRC*
- Kidney Cancer
- 12 total requests made YTD

2020 2022 2023 2021

Figure 2: Highlighted Accepted Requests

Genetic/Familial High-Risk Assessment: Colorectal November 2020

PREMM risk cutoff adjusted from 5% to 2.5%

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic

March 2021

Clarified verbiage to say 3 relatives with breast <u>OR</u> prostate cancers

Genetic/Familial High-Risk Assessment: Colorectal November 2022

- Tumors outside of endometrial and colon included in Lynch syndrome criteria
- Family history of polyposis included in criteria

Table 1: Detail of NCCN Submission Requests

Submitted	Guideline	Number of Requests	Number approved
11/2020	CRC*	6	1
3/2021	BOP**	8	3
5/2021	Uterine Neoplasms	1	1
8/2021	Gastric Cancer	7	0
11/2021	CRC*	7	1
2/2022	BOP**	7	0
3/2022	Kidney Cancer	3	2
4/2022	Prostate Cancer	3	0
8/2022	Gastric Cancer	3	0
11/2022	CRC*	4	2
3/2023	BOP**	2	1
3/2023	Kidney Cancer	3	2
4/2023	Prostate Cancer	3	Pending
6/2023	Gastric Cancer	4	Pending

^{*} Genetic/Familial High-Risk Assessment: Colorectal

** Genetic/Familial High-Risk Assessment: Breast, Ovarian and Pancreatic

Figure 3: Sample Letter



